Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Partnering

In view of our vision of a world free of pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

Explore our media section and access a range of materials relating to our company, people, medicines and medical devices.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2013 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Media - Our stories

Explore our recent stories to see what drives us

10 January 2023

Acquisition of Crestor™

Acquisition of Crestor™

“Our M&A strategy is designed to enrich our portfolio of brands. We achieve this partly through the acquisition of established brands irrespective of the therapeutic area.”

Quentin Le Masne de Chermont

Head of Corporate Strategy and Portfolio Management

Grünenthal acquired the European rights (excluding Spain and the UK) to Crestor™ (rosuvastatin) from AstraZeneca in February 2021.

This product is a statin, also known as a lipid-lowering medicine. It blocks an enzyme in the liver from causing the liver to make less cholesterol, while it also increases the uptake and breakdown of cholesterol by the liver. Crestor™ is used to treat blood lipid disorders and prevent cardiovascular events like heart attacks and strokes, which are among the most burdensome diseases in Europe¹.

Crestor™ is approved as a lipid-regulating medicine in more than 100 countries. With this agreement, Grünenthal acquired the exclusive rights to market Crestor™ and its second brands in more than 30 European markets. The company will also take over bulk production and packaging for the defined markets by 2025.

^{1 Townsend N, Wilson L, Bhatnagar P et al. Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal. 2016;37: 3232-3245.}

Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™ (rosuvastatin) (PDF)

Grünenthal agrees to acquire European rights to CRESTOR™ (rosuvastatin) from AstraZeneca (PDF)

Further details on our company can be found in our annual report.

Get in touch

We are keen to hear new ideas and discover assets that are relevant to our business. If you are interested in partnering with us, get in touch.

M-N/A-DE-01-23-0007

Partnering, Strategy